17.21
+2.64(+18.12%)
Currency In USD
| Previous Close | 14.57 |
| Open | 14.68 |
| Day High | 17.99 |
| Day Low | 14.08 |
| 52-Week High | 17.96 |
| 52-Week Low | 7.78 |
| Volume | 465,087 |
| Average Volume | 166,433 |
| Market Cap | 238.25M |
| PE | -11.79 |
| EPS | -1.46 |
| Moving Average 50 Days | 9.4 |
| Moving Average 200 Days | 10.24 |
| Change | 2.64 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $3,442 as of December 25, 2025 at a share price of $17.21. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $1,111.76 as of December 25, 2025 at a share price of $17.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
GlobeNewswire Inc.
Dec 22, 2025 11:00 AM GMT
STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designat
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
GlobeNewswire Inc.
Dec 15, 2025 11:00 AM GMT
STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
GlobeNewswire Inc.
Dec 08, 2025 11:00 AM GMT
STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno